Important advances have been made in the management of IBD in 2011. Research has focused on optimizing the currently available therapies and taking a more tailored approach to each individual patient.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Gut microbiome composition and function in experimental colitis during active disease and treatment-induced remission
The ISME Journal Open Access 06 February 2014
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Barrett, J. C. et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat. Genet. 40, 955–962 (2008).
Rutgeerts, P. et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353, 2462–2476 (2005).
Reinisch, W. et al. Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut 60, 780–787 (2011).
Pineton de Chambrun, G., Peyrin-Biroulet, L., Lemann, M. & Colombel, J. F. Clinical implications of mucosal healing for the management of IBD. Nat. Rev. Gastroenterol. Hepatol. 7, 15–29 (2010).
Colombel, J. F. et al. Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis. Gastroenterology 141, 1194–1201 (2011).
Colombel, J. F. et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N. Engl. J. Med. 362, 1383–1395 (2010).
Van Assche, G. et al. Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut http://dx.doi.org/gutjnl-2011-300755.
Louis, E. et al. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology http://dx/doi.org/10.1053/j.gastro.2011.09.034.
Beaugerie, L. et al. Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study. Lancet 374, 1617–1625 (2009).
Coelho, J. et al. Pregnancy outcome in patients with inflammatory bowel disease treated with thiopurines: cohort from the CESAME Study. Gut 60, 198–203 (2011).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
W. J. Sandborn declares that he has received research support from Abbott and Janssen, acted as a consultant for Abbott, Janssen and Merck and been a member of a speaker's bureau for Janssen. G. P. Pineton de Chambrun declares no competing interests.
Rights and permissions
About this article
Cite this article
de Chambrun, G., Sandborn, W. Advances in IBD management—towards a tailored approach. Nat Rev Gastroenterol Hepatol 9, 70–72 (2012). https://doi.org/10.1038/nrgastro.2011.248
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2011.248
